Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus Cadonilimab in advanced bile duct adenocarcinoma
NCT06092645Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, cadonilimab in cholangiocarcinoma (CCA), gallbladder carcinoma, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
surufatinibcadonilimab
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT06092645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092645.